Skip to main content
Premium Trial:

Request an Annual Quote

Clearbridge Signs China Distribution, Test Development Deal with Agen Lab

NEW YORK (360Dx) – Clearbridge Health Limited said today that it has entered into an exclusive partnership with Hunan, China's Agen Medicine Laboratory Technology Company, under which it will provide the firm with its ClearCell FX1 System for circulating tumor cell enrichment, offer training and assistance in Agen's development of laboratory developed tests, and then market those tests in China.

Financial terms of the deal were not disclosed.

ClearCell FX1, which was designed and manufactured by Singapore-based Clearbridge BioMedics, is an automated system for isolating and enriching wholly intact, viable CTCs from blood.

Clearbridge Executive Director and CEO Jeremy Yee said in a statement that the company believes this new collaboration will result in its platform being incorporated into a "suite of LDTs" to support more accurate, broader cancer diagnosis and treatment.

The Scan

Less Than Half

An effort to reproduce key findings from high-profile preclinical cancer studies finds less than half could be replicated, according to the Scientist.

Still Some SARS-CoV-2 Sequencing Holes

The Wall Street Journal reports that viral genomic surveillance has improved in the US, though says there are still gaps.

Avoiding Passing Them On

People with known disease-linked genetic variants are turning to in vitro fertilization so as to not pass those variants to their children, the Washington Post says.

PNAS Papers on Long Cell-Free DNA in Maternal Plasma, Genetic Propensity for Voting

In PNAS this week: long, cell-free DNA of maternal and fetal origins identified in maternal plasma, and more.